Clinical trials: Normal Upper Extremity
Lymphedema
Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
The purpose of this study is to determine the safety and side effects of bevacizumab in subjects with lymphedema who will initially receive bevacizumab alone and then in combination with standard manual lymphatic drainage (MLD)…
- Trial name
- NCT00318513
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Premiere Oncology of Arizona
Neuroendocrine Tumors
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE.
- Trial name
- NCT02743741
- Testing
- Lutetium-177 Octreotate
- Where
- 4 sites in Canada
- Volunteers
- 195 people
- Sponsor
- University Health Network, Toronto
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Acne Vulgaris
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study. The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl…
- Trial name
- NCT02005666
- Testing
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel
- Where
- 36 sites in United States, India
- Volunteers
- 850 people
- Sponsor
- Zydus Lifesciences Limited
Acne
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe…
- Trial name
- NCT02932306
- Testing
- IDP-121 Lotion, IDP-121 Vehicle Lotion
- Where
- 39 sites in United States
- Volunteers
- 820 people
- Sponsor
- Bausch Health Americas, Inc.
Cutaneous Leihmaniasis
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system.
- Trial name
- NCT07463040
- Testing
- Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin
- Where
- 3 sites in Ethiopia
- Volunteers
- 900 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Viral Wart, Delayed Hypersensitivity
Auto-inoculation of a Wart in Multiple Viral Warts
This study is being conducted to see effectiveness of auto-inoculation of a wart in multiple viral warts. Patients with recurrent, multiple warts of all types, are being recruited for the study.
- Trial name
- NCT04947332
- Testing
- Auto-inoculation
- Where
- Pakistan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Chronic Lower Leg Ulcer, Diabetic Lower Extremity Ulcers
Use of Hydroprep Wound Therapy With Motion Negative Pressure Therapy for Treatment of Chronic Lower Extremity Wounds
Use of a motorized waterjet to debride wounds to improve healing outcomes.
- Conditions
- Chronic Lower Leg Ulcer, Diabetic Lower Extremity Ulcers, Pressure Injuries, Traumatic Wounds and Injuries
- Trial name
- NCT07653165
- Testing
- Motion NPWT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- West Boca Center for Wound Healing
Sarcoma
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
- Trial name
- ALTER-S001 (NCT03880695)
- Testing
- Anlotinib+ Liposomal Doxorubicin
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Mucopolysaccharidosis I
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I. Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate…
- Trial name
- NCT05134571
- Testing
- Laronidase
- Where
- 5 sites in China
- Volunteers
- 12 people
- Sponsor
- Genzyme, a Sanofi Company
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Inherited Metabolic Disorders (IMD)
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT03406962
- Testing
- MGTA-456
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Magenta Therapeutics, Inc.
Herpes Labialis
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis.
- Trial name
- NCT00878072
- Testing
- Famciclovir
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Neuroblastoma
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen…
- Trial name
- NCT02919046
- Testing
- GD2-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
- Trial name
- NCT06585514
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital